Climb Bio, Inc. · NASDAQ:CLYM
Climb Bio — Investor Presentation (October 2026)
59 slides from Climb Bio's investor presentation, Oct 26, 2026
Slide 1: Corporate Presentation October 2026
Corporate Presentation OCTOBER 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” including, without limitation, statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug a
Slide 3: Our Mission: Scaling New Heights in Immune Medicines
Deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases Scaling New Heights in the Development of Transformative Immune Medicines 3 OUR MISSION
Slide 4: Corporate Highlights
Developing differentiated, monoclonal antibody (mAb) therapeutics for immune-mediated diseases, including those affecting kidney health, with expansive commercial opportunities Leveraging clinically validated B cell targets, proven mAb modality, and indications with well-defined endpoints and establ
Slide 5: Climb Bio: Data-Rich 2026
Budoprutug ITP Initial Ph1b data – June B cell and platelets, low dose cohort Climb Bio: Data-Rich 2026 Delivered on 2026 data guidance, with budoprutug SLE and ITP readouts to close out the year 2026 FPI = first patient in, HV = healthy volunteers, ITP = immune thrombocytopenia, PD = pharmacodyna
Slide 6: Pipeline of Highly Differentiated mAbs
Pipeline of Highly Differentiated mAbs Budoprutug SC and CLYM116 Phase 1 trials conducted in healthy volunteers. *Greater China defined as mainland China, Hong Kong, Macau, and Taiwan; Partner: Beijing Mabworks Biotech Co., Ltd. APRIL = a proliferation-inducing ligand, IV = intravenous, mAbs = monoc
Slide 7: Pursuing Expansive Market Opportunities
Pursuing Expansive Market Opportunities Addressing the needs of patients living with B cell-mediated diseases ANCA-AAV = antineutrophil cytoplasmic antibody-associated vasculitis, CIDP = Chronic inflammatory demyelinating polyradiculoneuropathy, IgAN = IgA Nephropathy, ITP = Immune Thrombocytopenia,
Slide 8: Climb Bio Team Poised to Deliver for Patients
Climb Bio Team Poised to Deliver for Patients Douglas E. Williams, PhD Independent, Chairman Aoife Brennan, MB, ChB Bo Cumbo CEO, Solid Biosciences Kim Drapkin, CPA Independent Judith Dunn, PhD President, Head of R&D, Vima Therapeutics Breanna O’Reilly, PhD Analyst, RA Capital Stephen Thomas, PhD CE
Slide 9: CLYM116
CLYM116 Anti-APRIL mAb @ CLIMBBIO
Slide 10: CLYM116: A Potential Best-in-Class anti-APRIL mAb
CLYM116: A Potential Best-in-Class anti-APRIL mAb *NAVIGATE-2 (NCT07375758) is being conducted in collaboration with our partner, Beijing Mabworks Biotech. APRIL = a proliferation-inducing ligand, Gd = galactose deficient, HV = healthy volunteer, IgAN = IgA nephropathy, PFS = pre-filled syringe Init
Slide 11: IgA Nephropathy: Progressive, Lifelong Renal Disease
Autoantibody mediated disease caused by deposition of immune complexes in the glomeruli, which leads to proteinuria, kidney injury, and loss of kidney function Diagnosed early in life (typically, ages 15-40)1; patients at risk for renal failure as disease progresses Lifelong disease – patients likel
Slide 12: KDIGO Guidelines Highlight Impact of IgA Reduction in IgAN
KDIGO Guidelines Highlight Impact of IgA Reduction in IgAN KDIGO commentary includes anti-APRIL therapies as a core pillar in the treatment of IgAN, reinforcing need for disease modifying treatments that stop production of pathogenic IgA (Gd-IgA1) APRIL = a proliferation-inducing ligand, IgAN = IgA
Slide 13: APRIL is a Validated Target in IgAN
APPROVED BLA FILED @ APPROVED APRIL is a Validated Target in IgAN with Further Potential to Unlock Phase 3 results and recent approvals establish the APRIL class and create an opportunity for differentiated next-generation therapies *Phase 3 eGFR data not yet available. APRIL = a proliferation-induc
Slide 14: CLYM116 Is The Only Known Sweeper Anti-APRIL
CLYM116 Is The Only Known “Sweeper” Anti-APRIL In Development Potential best-in-class anti-APRIL mAb, designed for improved activity, less frequent dosing, and favorable safety profile APRIL = a proliferation-inducing ligand, mAb = monoclonal antibody pH-dependent binding to APRIL Clinically validat
Slide 15: CLYM116 Sweeper Designed for a Differentiated Clinical Profile
CLYM116 “Sweeper” Designed for a Differentiated Clinical Profile pH-dependent binding and FcRn recycling allow CLYM116 to release captured APRIL for degradation and re-enter circulation to bind again APRIL = a proliferation-inducing ligand, mAb = monoclonal antibody Deeper target suppression Repeate
Slide 16: Phase 1 Data Support Best-in-Class Potential of CLYM116
Phase 1 Data Support Best-in-Class Potential of CLYM116 Data from healthy volunteer study demonstrate differentiation across key clinical attributes Luo ASN 2026; Liang ASN 2026 APRIL = a proliferation-inducing ligand, DLTs = dose limiting toxicities, Gd = galactose deficient, SAEs = serious adverse
Slide 17: CLYM116 Global Phase 1 Strategy in Healthy Volunteers
CLYM116 Global Phase 1 Strategy In Healthy Volunteers Data demonstrating deep, durable APRIL suppression and robust Gd-IgA1 reduction presented at ASN Kidney Week 2026 Luo ASN 2026; Liang ASN 2026 APRIL = a proliferation-inducing ligand, IgAN = IgA nephropathy, MAD = multiple ascending dose, SAD = s
Slide 18: CLYM116 Demonstrated Favorable Safety and Tolerability in HV
Safety CLYM116 Demonstrated Favorable Safety and Tolerability in HV Well-tolerated across 25-1280 mg, with no treatment-related SAEs or hypogammaglobulinemia Pooled across Australia Phase 1 (25-480 mg SAD; 320 mg Day 1 and Day 15 MAD) and China Phase 1 (40-1280 mg SAD). Source: Luo ASN 2026; Liang A
Slide 19: CLYM116 Exposure Profile Supports Long Dosing Interval
CLYM116 Exposure Profile Supports Long Dosing Interval ~33-day half-life, ~3.5x longer than sibeprenlimab, with dose-proportional exposure and consistent PK across the Australia and China studies Mean serum concentration after a single SC dose (n=6 per cohort); error bars show +SEM. Projected half-l
Slide 20: CLYM116 Achieved Rapid and Sustained Free APRIL Suppression
CLYM116 Achieved Rapid and Sustained Free APRIL Suppression ≥90% free APRIL suppression through Week 12 with single doses ≥480 mg, consistent across the Australia and China studies Median % change from baseline after a single SC dose; error bars show the upper quartile (Q3); MAD = 320 mg on Day 1 an
Slide 21: CLYM116: Longer APRIL Suppression vs. Sibeprenlimab
Above reflects cross-trial comparisons of observed single-dose healthy-volunteer data and not data from head-to-head studies; cross-trial comparisons are limited by differences in study design, populations, assays, regimens, and follow-up. CLYM116 free APRIL shown as median and sibeprenlimab as mean
Slide 22: CLYM116 Demonstrated ~70% Reduction in Gd-IgA1
CLYM116 Demonstrated ~70% Reduction in Gd-IgA1 Deep, durable reductions in Gd-IgA1, IgA and IgM Source: Liang ASN 2026; Luo ASN 2026 Left: China Phase 1, 800 mg SAD, Right: Australia Phase 1 SAD (placebo pooled, n=11) and China Phase 1 SAD. Australia MAD cohort (320 mg Day 1 and Day 15) achieved 78%
Slide 23: CLYM116 PK/PD Modeling Supports Q12W Dosing
CLYM116 PK/PD Modeling Supports Q12W Dosing 400 mg Q12W regimen predicted to keep median trough concentrations ~4x above APRIL EC75 and maintain near-complete APRIL suppression through 48 weeks Source: Luo ASN 2026; Liang ASN 2026. Simulated serum concentrations are derived from a population pharmac
Slide 24: CLYM116 NAVIGATE-2 Phase 2 Study in IgAN
RANDOMIZED, OPEN-LABEL STUDY, N ~30 / COHORT Initial data anticipated in H1 2027; designed to confirm integrated Phase 1 PK/PD modeling and support advancing Q12W regimen into Phase 3 CLYM116 NAVIGATE-2 Phase 2 Study in IgAN Ongoing Population: Adults with biopsy-proven IgAN 24-hour UPCR ≥ 0.5 g/g o
Slide 25: CLYM116: Compelling Phase 1 Data, Clear Path Ahead
CLYM116: Compelling Phase 1 Data, Clear Path Ahead CLYM116 offers the potential for durable disease control with convenient Q12W dosing; NAVIGATE-2 Phase 2 ongoing and device development advancing HV = healthy volunteer, PD = pharmacodynamics, PFS = pre-filled syringe Pivotal Study & Commercial Devi
Slide 26: Budoprutug
Budoprutug Anti-CD19 Fa @ CLIMBBIO
Slide 27: Budoprutug: A Differentiated Anti-CD19 Approach
Budoprutug: A Differentiated Anti-CD19 Approach CRS = cytokine release syndrome, ICANS = immune effector cell associated neurotoxicity syndrome, IV = intravenous, mAb = monoclonal antibody, pM = picomolar, SC = subcutaneous Cortazar ASN 2024 Durable B cell depletion, long dosing interval, with poten
Slide 28: CD19 is Emerging as a Preferred Pan-B-Cell Target
CD19 is Emerging as a Preferred Pan-B-Cell Target CLP = common lymphoid progenitor, GC = germinal center, mAbs = monoclonal antibodies 1 Adapted from Suan J Immunol 2025, 2 Tur Annals Rheum Dis 2024 Broad B-cell expression profile with potential for achieving deeper and more durable B-cell depletion
Slide 29: Budoprutug is a Highly Potent, Fc-Enhanced Anti-CD19 mAb
Budoprutug is a Highly Potent, Fc-Enhanced Anti-CD19 mAb Designed for optimal biological activity, with potential for both IV and subcutaneous administration ADCC = antibody-dependent cellular cytotoxicity, mAb = monoclonal antibody, pM = picomolar 18 pM precisely-tuned, low-fucosylated Fc region in
Slide 30: Developing Budoprutug Across Multiple Diseases
Developing Budoprutug Across Multiple Diseases Pursuing development in lead indications with high unmet need and clear B-cell driven pathology mAb = monoclonal antibody, QoL = quality of life 1 McGrogan Nephrol Dial Transplant 2011, 2 U.S. Census Estimates 2020-2025, 3 Feudjo-Tepie 2008, 4 Izmirly A
Slide 31: Primary Membranous Nephropathy
Primary Membranous Nephropathy Seferiana, living with pMN
Slide 32: Primary Membranous Nephropathy: Progressive Renal Disease
Autoantibody mediated disease characterized by proteinuria, nephrotic syndrome and progressive loss of renal function Untreated, ~30% progress to end-stage renal disease within 10 years and another 30% develop chronic kidney disease Rituximab used off-label and considered first-line, but only 35% of
Slide 33: Large Addressable Patient Population in pMN
Large Addressable Patient Population in pMN Majority of patients who do not achieve spontaneous remission will require treatment to prevent risk of progressive loss of kidney function PLA2R = phospholipase A2 receptor, pMN = primary membranous nephropathy 1 McGrogan Nephrol Dial Transplant 2011; ~1
Slide 34: Completed Phase 1b Study Established Proof-of-Concept in pMN
Completed Phase 1b Study Established Proof-of-Concept in pMN Budoprutug evaluated in an open-label, dose escalation study in adult patients with pMN NCT04652570; IV = intravenous, LTFU = long term follow-up, PLA2R = phospholipase A2 receptor, pMN = primary membranous nephropathy, UPCR = urine protei
Slide 35: Clinical Proof-of-Concept Demonstrated in Pilot Study in pMN
AEs = adverse events, DLTs = dose limiting toxicities, LLOQ = lower limit of quantification, PLA2R = phospholipase A2 receptor, pMN = primary membranous nephropathy, SAEs = serious adverse events, UPCR = urine protein creatinine ratio . 1 Cortazar ASN 2024, 2 Cortazar ASN 2025; Phase 1b pMN: budopru
Slide 36: Budoprutug Has a Highly Compelling Profile in pMN
Budoprutug Has a Highly Compelling Profile in pMN High serologic remission (anti-PLA2R negativity) and complete clinical remission rates support a potentially strong and differentiated clinical profile IV = intravenous, PLA2R = phospholipase A2 receptor, pMN = primary membranous nephropathy, q6m = e
Slide 37: PrisMN: Budoprutug Phase 2 pMN Study Enrolling
PrisMN: Budoprutug Phase 2 pMN Study Enrolling Biomarker endpoint provides potential to rapidly identify dose to carry forward into Phase 3; initial data presented at ASN with additional data anticipated in 2027 NCT07096843; eGFR = estimated glomerular filtration rate , Ig = immunoglobulin, IV = int
Slide 38: PrisMN: Patient Demographics and Initial Safety Data
PrisMN: Patient Demographics and Initial Safety Data Budoprutug was generally well tolerated in the 200 mg and 600 mg cohorts, which enrolled patients with high proteinuria and PLA2R Ab levels at baseline *downgraded from initial SAE assignment 600 mg baseline data incomplete (UPCR n=13; anti-PLA2R
Slide 39: PrisMN: PK/PD Data Support Rapid, Deep B Cell Depletion
CD20+ mean (SEM); absolute count (cells/mL) PrisMN: PK/PD Data Support Rapid, Deep B Cell Depletion Higher rate of clearance and deeper B-cell depletion observed with 600 mg 1 Data on file. Source: Cortazar ASN 2026. PK = pharmacokinetics, PopPK = population PK, UPCR = urine protein-creatinine ratio
Slide 40: PrisMN: Encouraging Reductions in Anti-PLA2R
0 -80 -60 -40 -20 0 2 4 8 12 PrisMN: Encouraging Reductions in Anti-PLA2R Low-dose budo demonstrated promising impact on anti-PLA2R Ab levels and early positive signal for 24hr UPCR at Week 12 Anti-PLA2R at Week 12 %CFB, individual participants Immunologic remission achieved in 5/13 (38%) overall an
Slide 41: Low-Dose Budoprutug Week 12 PLA2R Rivals Obinutuzumab RP3D
Low-Dose Budoprutug Week 12 PLA2R Rivals Obinutuzumab RP3D At just 200 mg, budoprutug reduced anti-PLA2R by 70% at Week 12, in line with prior Phase 1b results, and within range of other agents at Phase 3 or expected labeled doses (−22% to −85%) BL = baseline, EXP = expected, NR = not reported; PLA2
Slide 42: PrisMN: Encouraging Preliminary Data at Lowest Dose
PrisMN: Encouraging Preliminary Data at Lowest Dose Enrollment and follow-up are ongoing; additional data expected in 2027 Promising PLA2R Ab reduction and immunologic remission rate consistent with Phase 1b observations at Week 12 BIOMARKERS Budoprutug has been generally well tolerated at doses of
Slide 43: Immune Thrombocytopenia
Immune Thrombocytopenia John, living with ITP
Slide 44: Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia (ITP) Autoantibody mediated disease characterized by the destruction of platelets Results in bruising, bleeding episodes, hemorrhage and fatigue Chronic bleeding disorder Guidelines recommend corticosteroids as 1L treatment, TPO- RAs, rituximab, or splenectomy as 2L, however
Slide 45: Significant Opportunity for a Disease Modifying Approach in ITP
Significant Opportunity for a Disease Modifying Approach in ITP Chronic ITP patients often cycle through multiple therapies to maintain platelet control ~80-85% Require Initial Therapy3,4 3L = third line, ITP = immune thrombocytopenia 1 Feudjo-Tepie 2008, 2 U.S. Census Estimates 2020-2025,3 Moulis H
Slide 46: Strong Rationale for CD19 Approach in ITP
Strong Rationale for CD19 Approach in ITP Potent anti-CD19 approach offers the promise of sustained elimination of pathogenic B cells Broader expression of CD19 across B cell lineage may overcome limitations of anti-CD20 therapies CD19+/CD20- plasma cells expand within B cell niches post anti-CD20 t
Slide 47: Budoprutug Phase 1b ITP Trial Ongoing
TREATMENT PERIOD Week 0 Week 36 Week 12 Week 48 Week 24 LTFU = Budoprutug IV (2 doses, 14 days apart at Week 0 and Week 24) Budoprutug Phase 1b ITP Trial Ongoing Designed to define dose and regimen, and establish depth and duration of platelet response and B cell depletion; additional data from 500
Slide 48: ITP Phase 1b: Patient Demographics and Initial Safety Data
ITP Phase 1b: Patient Demographics and Initial Safety Data Budoprutug was generally well tolerated in the 250 mg and 500 mg cohorts, which enrolled heavily pretreated patients with persistent or chronic ITP AE = adverse event, ITP = immune thrombocytopenia, SAE = serious adverse event, TPO-RA = thro
Slide 49: Clinical Proof-of-Concept Demonstrated in ITP Phase 1b
>90% mean B-cell depletion at Week 4 66% (4/6) patients achieved a durable platelet response 33% (2/6) patients achieved a complete platelet response Participants with complete response maintained platelet levels ≥100 x 103/µL for ≥24 weeks; both previously relapsed on rituximab 75% (3/4) participan
Slide 50: Systemic Lupus Erythematosus
Systemic Lupus Erythematosus Marisa, living with SLE
Slide 51: Systemic Lupus Erythematosus (SLE)
High unmet need Steroids given first-line but are not a long-term solution ~50% of patients on approved biologics relapse Off-label rituximab is a mainstay of treatment, underscoring need for more effective therapies Chronic autoimmune condition Autoreactive lymphocytes and autoantibodies mistakenly
Slide 52: Strong Rationale for Anti-CD19 mAb in SLE
Strong Rationale for Anti-CD19 mAb in SLE CD19 mAb approach could provide optimal profile of disease control, safety, and broad patient accessibility mAb approach can overcome key CAR T-cell challenges Low risk of CRS and ICANS, no lymphodepletion required Long treatment interval with the ability to
Slide 53: Parallel Global and China SLE Studies Enrolling
Parallel Global and China SLE Studies Enrolling Designed to assess safety, tolerability, B-cell depletion, and kinetics of B-cell subset repopulation Global study: NCT07011043 China study: NCT07564596; FPI = first patient in, IV = intravenous, LTFU = long term follow-up, SLE = systemic lupus erythem
Slide 54: Budoprutug – Subcutaneous (SC) Formulation
Budoprutug – Subcutaneous (SC) Formulation Anti-CD19
Slide 55: Budoprutug SC Formulation Provides Optionality and Differentiation
IV = intravenous, mAbs = monoclonal antibodies, SC = subcutaneous Source: FDA-approved labels. Concentration normalized to mg/mL; where multiple indications or dosing regimens are approved, the highest volume single dose was used Ability to formulate as both IV and SC provides optionality in develop
Slide 56: Robust B-cell Depletion Observed with Budoprutug SC in HV
AUC = area under the curve, HV = healthy volunteers, IV = intravenous, SC = subcutaneous Company data on file from Phase 1 placebo-controlled, single ascending dose study in HV (NCT07090655); 3 cohorts: SC 3 mg, SC 6 mg, IV 6 mg, with 8 subjects per SC cohort (6 budoprutug: 2 placebo) and 14 subject
Slide 57: Budoprutug SC: Future Direction
Budoprutug SC: Future Direction Data in NHPs and healthy volunteers support continued development of SC formulation, with plans to advance to a study in patients to confirm dose and regimen with initial data expected in 2027 NHPs = nonhuman primates, PD = pharmacodynamic, SC = subcutaneous Next Step
Slide 58: Looking ahead
Looking ahead @ CLIMBBIO
Slide 59: Climb Bio: Continuing the Ascent Into 2027
Climb Bio: Continuing the Ascent Into 2027 Numerous milestones across both assets through 2027, funded into 2H 2028 2026 79.8M† FULLY DILUTED SHARES OUTSTANDING *Cash, cash equivalents, and marketable securities as of June 30, 2026; †57.3 million common shares outstanding as of June 17, 2026 HV = he